Michael Schmidt
Stock Analyst at Guggenheim
(4.96)
# 25
Out of 5,055 analysts
119
Total ratings
76.34%
Success rate
46.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FHTX Foghorn Therapeutics | Initiates: Buy | $12 | $4.69 | +155.86% | 1 | Nov 7, 2025 | |
| INCY Incyte | Upgrades: Buy | $125 | $104.15 | +20.02% | 7 | Nov 3, 2025 | |
| GMAB Genmab | Upgrades: Buy | $43 | $30.26 | +42.10% | 3 | Sep 23, 2025 | |
| IMNM Immunome | Reiterates: Buy | $25 | $17.14 | +45.86% | 3 | Aug 25, 2025 | |
| MRSN Mersana Therapeutics | Maintains: Buy | $125 → $30 | $27.92 | +7.45% | 4 | Aug 14, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Buy | $10 | $3.96 | +152.53% | 6 | Aug 13, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Buy | $18 | $12.25 | +46.94% | 6 | Aug 13, 2025 | |
| CMPX Compass Therapeutics | Maintains: Buy | $10 → $12 | $4.83 | +148.45% | 5 | Aug 12, 2025 | |
| ONC BeOne Medicines AG | Maintains: Buy | $350 → $365 | $365.82 | -0.22% | 4 | Aug 7, 2025 | |
| ARVN Arvinas | Maintains: Buy | $16 → $15 | $10.57 | +41.91% | 6 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $10 | $8.17 | +22.40% | 1 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $33.54 | -49.31% | 1 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $67.75 | +18.08% | 4 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $20.69 | +117.50% | 2 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $15 | $23.76 | -36.87% | 1 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $52 | $64.94 | -19.93% | 1 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $10 | $6.29 | +58.98% | 1 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $16.62 | +92.54% | 3 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $20.80 | -61.54% | 2 | Apr 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 | $96.01 | +13.53% | 5 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $7.56 | +85.31% | 3 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $30.29 | - | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $41.65 | +0.84% | 10 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $0.47 | - | 1 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $5.51 | +262.98% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $1.34 | +499.25% | 3 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $35.99 | - | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 | $0.66 | +956.92% | 4 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.57 | - | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.35 | - | 2 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.23 | - | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $34 | $14.93 | +127.73% | 4 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $2.58 | +868.99% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $14.37 | +108.77% | 1 | Jul 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $6.20 | +319.35% | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.90 | - | 2 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $80 | $43.65 | +83.28% | 5 | Feb 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.18 | - | 6 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $4 → $5.5 | $4.52 | +21.68% | 2 | Nov 7, 2017 |
Foghorn Therapeutics
Nov 7, 2025
Initiates: Buy
Price Target: $12
Current: $4.69
Upside: +155.86%
Incyte
Nov 3, 2025
Upgrades: Buy
Price Target: $125
Current: $104.15
Upside: +20.02%
Genmab
Sep 23, 2025
Upgrades: Buy
Price Target: $43
Current: $30.26
Upside: +42.10%
Immunome
Aug 25, 2025
Reiterates: Buy
Price Target: $25
Current: $17.14
Upside: +45.86%
Mersana Therapeutics
Aug 14, 2025
Maintains: Buy
Price Target: $125 → $30
Current: $27.92
Upside: +7.45%
ADC Therapeutics
Aug 13, 2025
Reiterates: Buy
Price Target: $10
Current: $3.96
Upside: +152.53%
ORIC Pharmaceuticals
Aug 13, 2025
Reiterates: Buy
Price Target: $18
Current: $12.25
Upside: +46.94%
Compass Therapeutics
Aug 12, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $4.83
Upside: +148.45%
BeOne Medicines AG
Aug 7, 2025
Maintains: Buy
Price Target: $350 → $365
Current: $365.82
Upside: -0.22%
Arvinas
Aug 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $10.57
Upside: +41.91%
Aug 6, 2025
Maintains: Buy
Price Target: $8 → $10
Current: $8.17
Upside: +22.40%
Jul 8, 2025
Reiterates: Buy
Price Target: $17
Current: $33.54
Upside: -49.31%
Jun 25, 2025
Reiterates: Buy
Price Target: $80
Current: $67.75
Upside: +18.08%
Jun 24, 2025
Reiterates: Buy
Price Target: $45
Current: $20.69
Upside: +117.50%
May 23, 2025
Maintains: Buy
Price Target: $40 → $15
Current: $23.76
Upside: -36.87%
May 12, 2025
Reiterates: Buy
Price Target: $52
Current: $64.94
Upside: -19.93%
May 7, 2025
Maintains: Buy
Price Target: $30 → $10
Current: $6.29
Upside: +58.98%
May 6, 2025
Reiterates: Buy
Price Target: $32
Current: $16.62
Upside: +92.54%
Apr 4, 2025
Maintains: Buy
Price Target: $12 → $8
Current: $20.80
Upside: -61.54%
Mar 28, 2025
Reiterates: Buy
Price Target: $109
Current: $96.01
Upside: +13.53%
Mar 24, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $7.56
Upside: +85.31%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $30.29
Upside: -
Feb 12, 2025
Reiterates: Buy
Price Target: $42
Current: $41.65
Upside: +0.84%
Jan 22, 2025
Reiterates: Buy
Price Target: n/a
Current: $0.47
Upside: -
Dec 6, 2024
Reiterates: Buy
Price Target: $20
Current: $5.51
Upside: +262.98%
Nov 15, 2024
Maintains: Buy
Price Target: $12 → $8
Current: $1.34
Upside: +499.25%
Oct 7, 2024
Downgrades: Neutral
Price Target: n/a
Current: $35.99
Upside: -
Sep 30, 2024
Upgrades: Buy
Price Target: $7
Current: $0.66
Upside: +956.92%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.57
Upside: -
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $6.35
Upside: -
Jan 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.23
Upside: -
Nov 8, 2023
Maintains: Buy
Price Target: $40 → $34
Current: $14.93
Upside: +127.73%
Aug 10, 2021
Initiates: Buy
Price Target: $25
Current: $2.58
Upside: +868.99%
Jul 19, 2021
Initiates: Buy
Price Target: $30
Current: $14.37
Upside: +108.77%
May 18, 2021
Initiates: Buy
Price Target: $26
Current: $6.20
Upside: +319.35%
Apr 28, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.90
Upside: -
Feb 15, 2019
Upgrades: Outperform
Price Target: $80
Current: $43.65
Upside: +83.28%
Jan 17, 2019
Initiates: Outperform
Price Target: n/a
Current: $8.18
Upside: -
Nov 7, 2017
Maintains: Market Perform
Price Target: $4 → $5.5
Current: $4.52
Upside: +21.68%